



May 12, 2014

To Whom It May Concern

Company Name  日医工株式会社  
NICHIIKO

(Securities Code 4541 Tokyo Stock Exchange, First Section )

Representative :Yuichi Tamura  
President and CEO

Contact :Mitsuyuki Azuma  
Director of President Office  
Tel:076-442-7026

## Revision of the 6th Mid-term Business Plan "Pyramid"

Although the Nichi-Iko Group formulated and announced its 6th Mid-term Business Plan "Pyramid" for the four years from April 2012 to March 2016 in March 2012, we hereby give notice that there will be a partial revision to the plan in order to ensure flexible business management matching the changes in the business environment that has been seen via reviewing the last two years.

### 1. Changes in the Nichi-Iko Group environment and the market environment

- Accelerated business promotion of biosimilars  
Overseas business expansion and alliances with outside companies for biosimilars
- Acceleration of overseas business expansion  
Promoting full-scale entry into the United States
- Business succession of manufacturing subsidiaries  
Business succession of Astellas Group manufacturing subsidiary
- Medical service fee / NHI price revision  
Stronger policies for use of generic pharmaceuticals, generic NHI price (grouping, lowering initial listing prices), etc.

### 2. Changes of figures in the plan

As the environment has changed significantly since the plan was formulated, we will revise the 6th Mid-term Business Plan "Pyramid" for its remaining period from April 2014 to March 2016. We have raised net sales over the original plan, but as SG&A expenses will be increasing in consideration of outgoings for future global business expansion, we have revised sales, operating profit and ordinary profit.

Revised plan (Units: millions of yen)

	Sales	Operating Profit	Ordinary Profit
Ending March 2015	123,000	9,300	9,000
Ending March 2016	137,200	12,500	12,100